What question did this study set out to answer?

To evaluate the clinical and economic burden of neovascular age-related macular degeneration (nAMD) by disease stage and determine drivers of disease-related healthcare costs among commercially insured US individuals.

August 31, 2021Journal of Managed Care & Specialty PharmacyOpen Access

Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis

View Full Paper

Ask AI

Bookmark

Authors

AAArghavan AlmonyUniversity of Southern California KKKatelyn R. KeylounAbbVie (United States)BSBijal Shah‐ManekGenesis HealthCare

Discussion

Member takes

Implication

Retrospective cohort study reveals higher outpatient costs driven by active choroidal neovascularization in macular degeneration, highlighting potential savings from disease stabilization.

Key Points

To evaluate the clinical and economic burden of neovascular age-related macular degeneration (nAMD) by disease stage and determine drivers of disease-related healthcare costs among commercially insured US individuals.
Retrospective cohort analysis of claims data from the IQVIA PharMetrics Plus database (April 2016 to August 2017) identifying 6,076 patients with nAMD enrolled for ≥6 months baseline and ≥12 months follow-up.
Tracked eye-level disease status (active CNV, inactive CNV, inactive scar), anti-VEGF treatment regimens, health care resource utilization, direct costs, and fall/fracture incidents over 12 months.
Identified cost drivers via multivariate analysis and evaluated transition rates across disease states in an incident subset (N=1,081) with ≥18 months of follow-up.
Annual nAMD-related outpatient visit costs were roughly 4-fold higher for active CNV ($8,658 [SD = $11,612]) versus inactive CNV ($2,406 [SD = $5,510]) and roughly 7-fold higher than inactive scar ($1,198 [SD = $3,035]; P < 0.0001).
Among prevalent patients, 59.6% (n = 3,623) received anti-VEGF therapy (mean duration: 7.7 months; mean injections: 6.0), while about 10% experienced a fall or fracture claim during the 12-month follow-up.
Initial choice of anti-VEGF agent and injection frequency emerged as the primary significant drivers of total annual nAMD-related outpatient costs in both prevalent and incident groups (P < 0.0001).

Cite This Study

Almony et al. (2021) studied this question.

synapsesocial.com/papers/69d76a9bb1cb92dd1bb8b033 https://doi.org/10.18553/jmcp.2021.27.9.1260

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study reveals higher outpatient costs driven by active choroidal neovascularization in macular degeneration, highlighting potential savings from disease stabilization.

Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider